Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM).

被引：0
|
作者：
Bringhen, Sara
Richardson, Paul G.
Voorhees, Peter Michael
Plesner, Torben
Mellqvist, Ulf-Henrik
Zonder, Jeffrey A.
Reeves, Brandi Nikcole
Zavisic, Stojan
Harmenberg, Johan
Obermueller, Jakob
Sonneveld, Pieter
机构：
[1] Univ Torino, Div Hematol, Turin, Italy
[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Carolinas Hlth Care Syst, Levine Canc Inst, Charlotte, NC USA
[4] Vejle Hosp, Dept Hematol, Vejle, Denmark
[5] Boras Hosp, Boras, Sweden
[6] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[7] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[8] Oncopeptides AB, Stockholm, Sweden
[9] Erasmus MC, Rotterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8043
引用
收藏
页数：2
相关论文
共 50 条
  • [41] MELFLUFEN THERAPY FOR HEAVILY PRETREATED RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS REFRACTORY TO DARATUMUMAB AND/OR POMALIDOMIDE: EARLY EFFICACY DATA (HORIZON)
    Mateos, M., V
    Oriol Rocafiguera, A.
    Rodriguez-Otero, P.
    Blade, J.
    Larocca, A.
    Moreb, S. J.
    Cavo, M.
    Mazumder, A.
    Alegre, A.
    Hassoun, H.
    Maisel, C.
    Paner, A.
    Gabrail, N.
    Halka, K.
    Zonder, J.
    Ocio, E.
    Byrne, C.
    Harmenberg, J.
    Lindberg, J.
    Nordstrom, E.
    Thuresson, S.
    Richardson, G. P.
    HAEMATOLOGICA, 2018, 103 : 32 - 32
  • [42] OCEAN (OP-103): Melflufen/Dexamethasone Compared Wth Pomalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - Subgroup Analysis in Patients Refractory to Prior Alkylators
    Schjesvold, Fredrik
    Ludwig, Heinz
    Mateos, Maria-Victoria
    Abdulhaq, Haifaa
    Norin, Stefan
    Thuresson, Marcus
    Bakker, Nicolaas A.
    Richardson, Paul G.
    Sonneveld, Pieter
    BLOOD, 2022, 140 : 12607 - 12609
  • [43] AN ONGOING OPEN-LABEL PHASE 1/2A STUDY OF THE SAFETY AND EFFICACY OF MELFLUFEN AND DEXAMETHASONE COMBINATION FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM)
    Mellqvist, U. H.
    Paba-Prada, C.
    Palumbo, A.
    Plesner, T.
    Sonneveld, P.
    Voorhees, P.
    Byrne, C.
    Harmenberg, J.
    Nordstrom, E.
    Richardson, P. G.
    HAEMATOLOGICA, 2014, 99 : 375 - 376
  • [44] Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).
    Vij, Ravi
    Richardson, Paul Gerard Guy
    Jagannath, Sundar
    Siegel, David Samuel DiCapua
    Baz, Rachid C.
    Srinivasan, Shankar
    Larkins, Gail
    Zaki, Mohamed H.
    Hussein, Mohamad A.
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM)
    Pennipede, Dante
    Mohyuddin, Ghulam Rehman
    Hawkins, Ryan
    Ganguly, Siddhartha
    Shune, Leyla
    Ahmed, Nausheen
    Mohan, Meera
    Cui, Wei
    Mahmoudjafari, Zahra
    McGuirk, Joseph
    Atrash, Shebli
    Abdallah, Al-Ola
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 107 (06) : 602 - 608
  • [46] Anchor (OP-104): melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma (RRMM) - final efficacy and safety results
    Ocio, Enrique
    Efebera, Yvonne
    Hajek, Roman
    Straub, Jan
    Maisnar, Vladimir
    Eveillard, Jean-Richard
    Karlin, Lionel
    Mateos, Maria-Victoria
    Oriol, Albert
    Ribrag, Vincent
    Richardson, Paul
    Norin, Stefan
    Obermuller, Jakob
    Bakker, Nicolaas
    Pour, Ludek
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S204 - S204
  • [47] Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone
    San-Miguel, Jesus F.
    Dimopoulos, Meletios A.
    Stadtmauer, Edward A.
    Rajkumar, S. Vincent
    Siegel, David
    Bravo, Marie-Laure
    Olesnyckyj, Marta
    Knight, Robert D.
    Zeldis, Jerome B.
    Harousseau, Jean-Luc
    Weber, Donna M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (01): : 38 - 43
  • [48] Long-Term Outcomes and Safety of Continuous Lenalidomide Plus Dexamethasone (Len plus Dex) Treatment in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM)
    Dimopoulos, Meletios Athanasios
    Hussein, Mohamad
    Swern, Arlene S.
    Weber, Donna M.
    BLOOD, 2011, 118 (21) : 1263 - 1263
  • [49] HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety
    Richardson, Paul G.
    Oriol, Albert
    Larocca, Alessandra
    Rodriguez Otero, Paula
    Norkin, Maxim
    Blade, Joan
    Cavo, Michele
    Hassoun, Hani
    Leleu, Xavier
    Alegre, Adrian
    Maisel, Christopher
    Paner, Agne
    Mazumder, Amitabha
    Zonder, Jeffrey A.
    Puig, Noemi
    Harran, John
    Harmenberg, Johan
    Thuresson, Sara
    Zubair, Hanan
    Mateos, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S329 - S330
  • [50] Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR
    Weisel, K.
    Palumbo, A.
    Chanan-Khan, A.
    Nooka, A. K.
    Spicka, I.
    Masszi, T.
    Beksac, M.
    Hungria, V.
    Munder, M.
    Mateos, M-V.
    Mark, T. M.
    Spencer, A.
    Qi, M.
    Schecter, J.
    Amin, H.
    Qin, X.
    Deraedt, W.
    Ahmadi, T.
    Sonneveld, P.
    ANNALS OF ONCOLOGY, 2016, 27
12345